Moonshots EP 147: Stem Cells 101 — The Future of Medicine w/ Robert Hariri

Summary

A deep-dive stem cell primer with Dr. Robert Hariri (MD/PhD, CEO of Cellularity, 170+ patents), framed as “Stem Cells 101.” Hariri walks through the biology: every human starts from one totipotent stem cell that differentiates into 40 trillion cells across all tissue types, with undifferentiated stem cells retained in every organ as a natural repair kit. The key aging insight: stem cell populations decline ~1,000-fold from birth to age 80 (e.g., 1 in 20-30K bone marrow cells at birth vs. 1 in 20-30M at 80), directly correlating with declining repair capacity.

Hariri’s core innovation (30+ years ago) was recognizing the placenta as a “3D printer” for the baby — not merely a vascular connection — containing pristine, newborn-age stem cells that were routinely incinerated as medical waste. He built an industrial process to collect, process, and cryopreserve these cells. His company Cellularity (where Diamandis is Vice Chairman) and its consumer arm Life Bank USA offer placental stem cell banking. The conversation distinguishes between cord blood banking (hematopoietic/blood stem cells only, the older industry) and full placental tissue banking (multi-lineage stem cells capable of becoming any tissue type).

On regulation: Hariri is candid that the FDA’s conservative approach has kept stem cell therapies unavailable in the US while they’re accessible in Panama, Costa Rica, Mexico, Antigua, and Bali. He argues the safety data from decades of bone marrow transplants and international stem cell treatments shows no concerning long-term safety signal, and that the therapeutic potential outweighs the risk of regulatory inaction. He implies “other forces” beyond safety science are behind the resistance but doesn’t name them explicitly.

The stem cell supplementation thesis: as aging depletes your native stem cell reserves, exogenous stem cells (from banked placental tissue or potentially allogeneic sources) can restore regenerative capacity. Hariri frames this as the biological equivalent of reinstalling a “master boot disc” — uncorrupted software that can restore organ function.

Bias/Sponsor Notes

Extreme conflict of interest: Diamandis is Vice Chairman of Cellularity and co-founded Fountain Life and Human Longevity with Hariri. The episode is functionally a Cellularity/Life Bank USA infomercial. Viome ad read mid-episode. Hariri’s claims about stem cell safety are directionally supported but presented without counterpoint from regulatory scientists or discussion of the legitimate concerns (tumor risk, immune rejection) that underpin FDA caution.